Durham, North Carolina-based Precision BioSciences, a genome editing system provider, has raised $126.4 million for its IPO after pricing its 7.9 million shares at $16 per share. The stock began trading March 28, 2019 on the NASDAQ under the ticker symbol “DTIL.” JP Morgan, Goldman Sachs, Jefferies and Barclays are the underwriters. Precision BioSciences’ pre-IPO backers include ArrowMark Partners, Franklin Templeton Investments, Cowen Healthcare Investments, Brace Pharma Capital, Adage Capital Management, Cormorant Asset Management, Gilead Sciences, Vivo Capital, Alexandria Venture Investments, Ridgeback Capital, Agent Capital, Leerink Partners, venBio, F-Prime and Osage University Partners.
DURHAM, N.C., March 27, 2019 (GLOBE NEWSWIRE) — Precision BioSciences (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life (DTIL) through its proprietary ARCUS genome editing platform, today announced the pricing of its initial public offering of 7,900,000 shares of common stock at a public offering price of $16.00 per share, for total gross proceeds of $126.4 million, before deducting underwriting discounts and commissions and expenses payable by Precision. In addition, Precision has granted the underwriters a 30-day option to purchase up to 1,185,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares are being offered by Precision. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “DTIL” on Thursday, March 28, 2019. The offering is expected to close on April 1, 2019, subject to customary closing conditions.
J.P. Morgan, Goldman Sachs & Co. LLC, Jefferies and Barclays are acting as joint book-running managers for the offering.
A registration statement relating to the securities being sold in this offering was declared effective by the Securities and Exchange Commission on March 27, 2019. This offering is being made only by means of a prospectus. When available, copies of the final prospectus relating to this offering may be obtained by contacting: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone: (866) 803-9204 or email: email@example.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone: (866) 471-2526, facsimile: (212) 902-9316, or email: firstname.lastname@example.org; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone: (877) 547-6340 or email: Prospectus_Department@jefferies.com; or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone: (800) 603-5847.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Precision BioSciences
Precision BioSciences is dedicated to improving life (DTIL) through its proprietary genome editing platform, “ARCUS.” Precision leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and create healthy and sustainable food and agriculture solutions. Precision is actively developing product candidates in three innovative areas: allogeneic CAR T immunotherapy, in vivo gene correction, and food.